



UNICA

UNIVERSITÀ
DEGLI STUDI
DI CAGLIARI



Università di Cagliari

UNICA IRIS Institutional Research Information System

This is the Author's manuscript version of the following contribution:

Firinu Davide et al.

Diagnostic capabilities, clinical features and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort

Am J Hematol 2024 Feb;99(2):254-262.

The publisher's version is available at:

Cod. DOI

doi: 10.1002/ajh.27169.

When citing, please refer to the published version: PRE PRINT (OA)

Diagnostic capabilities, clinical features and longitudinal *UBA1* clonal dynamics of a nationwide VEXAS cohort

Carmelo Gurnari^{1,2}, Maria Rosaria Pascale¹, Antonio Vitale³, Elisa Diral⁴, Alessandro Tomelleri⁵, Elisa Galossi¹, Giulia Falconi¹, Alessandro Bruno⁴, Francesca Crisafulli⁶, Micol Frassi⁶, Chiara Cattaneo⁶, Diego Bertoli⁶, Massimo Bernardi⁴, Annalisa Condorelli⁷, Erika Morsia⁸, Antonella Poloni⁸, Elena Crisà⁹, Daniela Caravelli⁹, Paola Triggianese¹, Luisa Brussino¹⁰, Giorgia Battipaglia¹¹, Sara Bindoli¹², Paolo Sfriso¹², Federico Caroni¹³, Matteo Dragani¹⁴, Flavia Mallegni¹, Federica Pilo¹⁵, Davide Firinu¹⁵, Antonio Curti¹⁶, Cristina Papayannidis¹⁶, Attilio Olivieri⁸, Sharham Kordasti^{8,17}, Francesco Albano¹⁸, Fabrizio Pane¹¹, Pellegrino Musto¹⁸, Monica Bocchia¹³, Elisabetta Lugli¹⁹, Massimo Breccia²⁰, Marco Frigeni⁷, Lorenzo Dagna⁵, Raffaella Greco⁴, Franco Franceschini⁶, Corrado Campochiaro⁵, Luca Cantarini^{3*}, Maria Teresa Voso^{1*}

1 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

2 Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA

3 Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy

4 IRCCS San Raffaele Scientific Institute, Department of Onco-Hematology, Milan, Italy

5 Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS Ospedale San Raffaele & Vita-Salute San Raffaele University, Milan, Italy

6 ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy

7 Azienda SocioSanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

8 Hematology Department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Italy

9 Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy

10 Department of Medical Sciences Allergy and Clinical Immunology Unit University of Torino & Mauriziano Hospital Torino, Italy

11 Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy

12 Rheumatology Unit, Department of Medicine-DIMED, University of Padua, Italy

13 Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy

14 IRCCS San Martino Hospital, Genova

15 Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

16 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy

17 Haematology, Guy's Hospital & Comprehensive Cancer Centre, King's College, London, United Kingdom

18 Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University, Bari, Italy

19 Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy

[DATA]

CLEVELAND CLINIC FOUNDATION

[indirizzo della società]

20 Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, Rome,
59 Italy

60
61 * This symbol indicates equal contribution

62 **Correspondence:**

63 Dr. Carmelo Gurnari, MD

64 Department of Biomedicine and Prevention

65 Tor Vergata University, Viale Oxford 81, 00133, Rome, Italy

66 Email: carmelogurnari31@gmail.com; ORCID: 0000-0001-6829-5544

67
68 **Running title:** A cartography of VEXAS in Italy

69 **Keywords:** VEXAS, myelodysplastic syndrome, *UBA1* mutations, transplant

70 **Word Count**

71 **Abstract:** 250

72 **Text characters count:** 3119

73 **Figures/Tables:** 3/1

74 **References:** 35

75 **DECLARATIONS**

76 **Ethics approval and consent to participate.**

77 Review and collection of clinical and molecular data were performed in accordance with the protocols and written
78 consent approved by the institutional review boards of each participating institutions and guidelines set forth by
79 the Declaration of Helsinki.

80 **Conflict of interest disclosure**

81 The authors declare no competing financial interests.

82 **Funding statement:** This work was also supported by AIRC 5 × 1000 call “Metastatic disease: the key unmet
83 need in oncology” to MYNERVA project, #21267 (Myeloid Neoplasms Research Venture AIRC. A detailed

84 description of the MYNERVA project is available at <http://www.progettoagimm.it>). This work was also supported
85 by MUR-PNRR M4C2I1.3 PE6 project PE00000019 Heal Italia, PRIN grant 2017WXR7ZT, Ministero della
86 Salute, Rome, Italy (Finalizzata 2018, NET-2018-12365935; personalized medicine program on myeloid
87 neoplasms: characterization of the patient's genome for clinical decision making and systematic collection of
88 real-world data to improve quality of health care) (M.T.V.), C.G. was supported by a grant from the Edward P.
89 Evans Foundation.

90 **Author contributions**

91 CG, MRP and MTV supervised the project and wrote the manuscript. All the remaining authors contributed with
92 patient's data and samples and participated in the discussion, read, edited and approved the final version of this
93 manuscript, being accountable for all aspects of the work.

94 **Data availability statement**

95 All data and results of the survey from which results were generated are available in the manuscript. Additional
96 request can be directed via email to the corresponding author.

97 **Consent for publication**

98 Informed consent obtained according to the protocols approved by the Institutional Review Board of the
99 participating institutions and in accordance with the ethical principles set forth by the Declaration of Helsinki.

100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115

Abstract

VEXAS is a prototypic hemato-inflammatory disease combining rheumatologic and hematologic disorders in a molecularly defined nosological entity. In this nationwide study, we aimed at screenshotting the current diagnostic capabilities and clinical-genomic features of VEXAS, and tracked *UBA1* longitudinal clonal dynamics upon different therapeutics, including allogeneic hematopoietic cell transplant.

We leveraged a collaboration between the Italian Society of Experimental Hematology and of Rheumatology and disseminated a national survey to collect clinical and molecular patient information.

Overall, 13/29 centers performed *UBA1* genomic testing locally, including Sanger sequencing (46%), next-generation sequencing (23%), Droplet Digital PCR (8%), or combination (23%). A total of 41 male patients were identified, majority (51%) with threonine substitutions at Met41 hotspot, followed by valine and leucine (27% and 8%). Median age at VEXAS diagnosis was 67 years. All patients displayed anemia (median hemoglobin 9,1 gr/dL), with macrocytosis. **Bone marrow vacuoles were observed in most cases (89%).** The most common rheumatologic association was polychondritis (49%). A concomitant MDS was diagnosed in 71% of patients (n=28), chiefly exhibiting lower IPSS-R risk profiles. Karyotype was normal in all patients, except 3 MDS cases showing -Y, t(12;16)(q13;q24), and +8. The most frequently mutated gene was *DNMT3A* (n=10), followed by *TET2* (n=3). At last follow-up, 5 patients died and 2 patients progressed to acute leukemia. Longitudinal *UBA1* clonal dynamics demonstrated mutational clearance following transplant.

We collected a nationwide interdisciplinary VEXAS patient cohort, characterized by heterogeneous rheumatologic manifestations and treatments used. MDS was diagnosed in 71% of cases. Patients exhibited various longitudinal *UBA1* clonal dynamics.

137

138 **Abbreviations**

139

140 Allo-HCT

141 AML: acute myeloid leukemia

142 ARCH: Age-related clonal hematopoiesis

143 BM bone marrow

144 CHIP: Clonal hematopoiesis of indeterminate potential

145 ddPCR: droplet digital polymerase chain reaction

146 IPSS-R/M: Revised/Molecular International Prognostic Scoring System

147 MDS: myelodysplastic neoplasm/syndromeVPa

148 MGUS: Monoclonal Gammopathy of Undetermined Significance

149 NGS: next generation sequencing

150 SIES: Italian Society of Experimental Hematology

151 SIR: Italian Society of Rheumatology

152 VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic)

153 WES: whole exome sequencing

154

155

156

157

158

159 **Introduction**

160 VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic) syndrome is a prototypic hemato-
161 inflammatory disease juxtaposing for the first time rheumatologic and hematologic disorders under the aegis of
162 a molecularly defined nosological entity.(1) Given its multifaceted clinical presentations, VEXAS represents a
163 challenging masquerade syndrome and it has elicited a wide medical interest. What makes this condition so hard

164 to be diagnosed is the variety of clinical manifestations that, taken individually, can be ascribed to many other
165 disorders. Indeed, VEXAS lies at the interface between bone marrow failure syndromes (macrocytic anemia),
166 "inflamm-aging" and clonal hematopoiesis, displaying a tetrad of somatic mutations, morphologic bone marrow
167 (BM) features, inflammatory pathways and immune overshooting.(2, 3)

168 Somatic mutations in the X-linked gene *UBA1* in hematopoietic stem and myeloid cells represent the genetic
169 underpinnings of the syndrome.(4) The presence of *UBA1*-mutant clonal hematopoiesis, typified by the
170 characteristics BM vacuoles(5), and the resultant perturbation of ubiquitylation and hyperinflammation(6), offers
171 a fertile soil for acquisition of further somatic myeloid gene mutations, in a disease continuum which often
172 culminates in the association with myelodysplastic syndromes/neoplasms (MDS).(7) Besides MDS, macrocytic
173 anemia (regardless of an overt MDS diagnosis), plasma cell dyscrasia, and recurrent thrombosis are among the
174 most frequent hematological features, whereas inflammatory manifestations encompass skin (chiefly, Sweet
175 syndrome or Sweet syndrome-like lesions), joints, lung, gastrointestinal, ocular and kidney involvement as well
176 as non-infectious fever, nose and ear chondritis.(8, 9) As a result, collaboration among different specialties is of
177 paramount importance to promptly identify and correctly diagnose patients, usually men in their 6-7th decade of
178 life.(10)

179 In a study exploring the prevalence of *UBA1* variants in the general population, exome data from 163,096
180 participants within the Geisinger MyCode Community Health Initiative were queried.(11) Disease-causing *UBA1*
181 variants were found in 1 in ~4000 men over 50 years, and in about 1 in 14,000 individuals, a prevalence similar
182 to that of MDS.(12)

183 Treatment strategies vary according to the specific clinical presentations and aim at suppressing the condition
184 of hypercytokynemia (e.g., with anti-interleukins), the *UBA1*-mutant clone (azacitidine, allogeneic hematopoietic
185 cell transplant, allo-HCT) or support therapy (growth factors for anemia, thrombotic and infectious prophylaxis,
186 among others).(8, 13, 14)

187 With the joint efforts of the Italian Society of Experimental Hematology (SIES) and the Italian Society of
188 Rheumatology (SIR), we aimed at screenshotting the current *UBA1* diagnostic capabilities and clinical-genomic
189 features of VEXAS in Italy, 2.5 years since its initial discovery.(1) We also collected patient outcomes and

190 performed longitudinal molecular studies in cases undergoing different therapeutic approaches, including allo-
191 HCT.

193 **Methods**

194 **Patients**

195 This study was conducted through a national survey, under the purview of SIES and SIR, mostly involved in the
196 clinical management of VEXAS patients. An electronic link was disseminated via email from September 2022 to
197 April 2023 with multiple rounds of reminders to ensure wide patient enrollment. Selection included all cases with
198 a diagnosis of VEXAS made by concomitant clinical evaluation and molecular *UBA1* screening (see below).
199 Centers were queried for relevant data concerning diagnostic capabilities (type of molecular analysis, number of
200 tests), and patients' characteristics including main laboratory values and treatment types. Along with this,
201 longitudinal sampling was performed for a sub-cohort of cases with canonical Met41 substitutions to study
202 variations of clonal burden upon different therapeutics. The study was approved by the institutional review board
203 of the participating centers and conducted in accordance with the Declaration of Helsinki and Good Clinical
204 Practice guidelines.

205 **Genomic studies**

206 Mutations of the *UBA1* gene were identified in DNA extracted both from peripheral blood (PB) and BM. The
207 fraction of mononuclear cells was isolated by separation with Ficoll-Hypaque. Genomic DNA was extracted using
208 the commercially available QIAamp DNA Blood Mini Kit Qiagen® (Qiagen Srl, Milan, Italy) according to the
209 manufacturer's instructions. *UBA1* mutations were screened by a variety of techniques (Sanger(5), next-
210 generations sequencing-NGS, droplet digital PCR-ddPCR(15), or whole exome sequencing-WES) depending
211 on center availability. To explore the variation of clonal dynamics from diagnosis and during follow-up in a subset
212 of patients with available DNA sampling, we designed ddPCR primers for the 3 hotpots substitutions at Met41
213 (Thr, Leu, Val) as previously shown for the Met41Val substitution.(15) **In addition, a 30-genes myeloid NGS panel**
214 **(SOPHiA GENETICS, Saint-Sulpice, Switzerland) was used to identify concomitant mutations on a MiniSeq®**

sequencing platform (Illumina, San Diego, California) for 23/41 cases with a strong suspicion for concomitant MDS, and calculate appropriate disease risk scoring systems, as detailed elsewhere.(16)

Statistics

Patients' characteristics were summarized by descriptive statistics to provide a summary of the collected information on the characteristics of the cohort and distribution of values. Quantitative variables were expressed as median, interquartile range, minimum and maximum. Qualitative variables were expressed as numbers and percentages. Overall survival (OS) was calculated from VEXAS symptoms onset to last follow-up or death and estimated with the Kaplan-Meier method. Analyses, graphs and data visualization were generated using the computing environment of Excel Microsoft Office 365, GraphPad Prism (8.4.0) and R software (4.0.0 R Core Team, R Foundation for Statistical Computing, Vienna, Austria).

Results

***UBA1* genomic testing in Italy: methods, availabilities and alterations**

Overall, 41 patients were diagnosed with VEXAS in 29 participating centers, 13 of which had *UBA1* genomic testing available (**Figure 1A**). This consisted of either Sanger sequencing (n=6, 46%), NGS (n=3, 23%) or ddPCR (n=1, 8%), whereas a combination of these methods was in use in 3 (23%) centers (**Figure 1B**). Over a median time of 13,7 months (interquartile range, IQR 4.2-18.5) since *UBA1* testing availability, the positivity rate reached 11,7% (n=41 out of 351 total tests). Approximately half (51%) of VEXAS cases harbored threonine substitutions at the Met41 hotspot, followed by valine and leucine (27% and 8%; **Figure S1**). Of note is that 3 patients had rare mutations of the *UBA1* gene, the new variant c.118-1G>C, identified at the splice acceptor site of exon 3 (n=2) and 1 had the rare c.167C>T, p.Ser56Phe. Furthermore, WES detected in 1 patient the c.1430G>C mutation of the gene *UBA1* in exon 14, which has been recently described and functionally characterized as pathogenic.(17) WES has been performed in this particular case for which the clinical suspicion of VEXAS was very high and the most common exon 3 variants had been excluded by Sanger sequencing.

Patient characteristics

A total of 41 patients, all males and with rheumatologic manifestations were accrued. Median age at VEXAS diagnosis was 67 years (IQR=62-72). All patients had anemia (median hemoglobin 9,1 gr/dL, IQR=8,3-10,8) and macrocytosis (median MCV 105 fL, IQR=97,3-109). The demographic and clinical characteristics of patients with VEXAS syndrome are summarized in **Table 1**. BM vacuoles were observed in myeloid and erythroid precursors, or both in the majority of cases (89%; **Figure 1C**). Skin manifestations were present in roughly a third (34%) of patients with forms ranging from Sweet Syndrome or neutrophilic dermatosis to erythematous plaques and skin rashes, as previously reported.(9) Rheumatological manifestations were heterogeneous, but the most frequent was relapsing polychondritis, typically involving ear and nose (49%, **Figure 1D**).

Notably, 37% of patients also showed MGUS (Monoclonal Gammopathy of Undetermined Significance) at serum protein electrophoresis evaluation, more frequently of the IgG subtype (n=9 IgG, n=3 IgM, none with IgA, n=3 cases with missing data). **None of these patients progressed to multiple myeloma at last follow-up.** Only in 1 case, a monoclonal B-cell lymphocytosis was associated with VEXAS syndrome.

Finally, 11 patients (27%) experienced thrombotic events, chiefly deep vein thrombosis (DVT), at disease onset which constituted reasons to seek medical attention along with the accompanying macrocytic anemia, and 3 presented more than 1 episode. All but one case (central retinal artery occlusion) originated in the venous district and anatomic sites were various: upper extremity DVT (31%), lower extremity DVT (38%), lower extremity DVT with pulmonary embolism (15%), splanchnic (8%) and superficial vein thrombosis (8%).

The clinical dyad of myelodysplastic syndrome and VEXAS

MDS was diagnosed in 71% (n=28) of our patients (**Figure 2A**), all falling into lower Revised International Prognostic Scoring System (IPSS-R scores <3,5(18)) categories except for two cases, who were still classified as intermediate ($\leq 4,5$). When re-stratified according to the recently released Molecular International Prognostic Scoring System (IPSS-M)(19), only two cases were upgraded from the IPSS-R moderate to the IPSS-M high-risk group, while the majority remained in the lower-risk categories (negative values, **Figure 2B**). Cytogenetics was normal in all but 3 MDS cases showing chromosome anomalies such as -Y, t(12;16)(q13;q24), and trisomy

264 8. A total of 2 patients did not satisfy the criteria for MDS but rather belonged to the nosological entity of clonal
265 cytopenia of undetermined significance (CCUS).

266 Overall, NGS analysis was performed in 23 cases (2 CCUS and 21 VEXAS/MDS), 74% of which harbored at
267 least 1 myeloid gene mutation, with a high frequency of *DNMT3A* (n=10), followed by *TET2* mutations (n=3) with
268 only 22% of these patients having >1 alteration. We previously described the first patient with VEXAS with
269 *ASXL1/SF3B1*-mutant MDS who evolved to AML (acute myeloid leukemia) upon acquisition of a *RUNX1*
270 mutation. We have now recorded an additional case of *TET2*-mutant MDS evolving to AML and succumbing
271 because of disease progression.

272 Treatment approaches

273 At the time of diagnosis, all but 3 patients had already received rheumatologic treatments: 12 patients had been
274 treated with corticosteroids only; 20 patients had received during their clinical history at least one
275 immunosuppressive agent, such as cyclosporine A, methotrexate, hydroxychloroquine, colchicine or
276 azathioprine; 11 patients had received anti-interleukin (IL)-1 inhibitor (anakinra and canakinumab); 8 had been
277 treated with anti-IL6 drug (tocilizumab), and 7 with JAK-inhibitors (baricitinib, ruxolitinib, tofacitinib, upadacitinib
278 and filgotinib). Overall, 21 patients underwent more than one line of treatment (including steroids), and the
279 median number of lines of treatment received was 3 (IQR=2-4) in the whole cohort (**Table 1**).

280 Of the 11 patients experiencing thrombosis, 2 were treated with warfarin, 1 with fondaparinux, 1 initially with
281 fondaparinux and then switched to the new direct oral anticoagulants (DOACs), 4 only with DOACs, and 3 with
282 low-molecular-weight heparins (LMWHs). Overall, 6 patients had discontinued anticoagulant therapy at last
283 follow-up.

284 The therapeutic approach for patients with MDS associated with VEXAS syndrome was based on disease risk
285 assessment according to general MDS treatment guidelines(20), mostly with erythropoietin and hypomethylating
286 agents (HMA). Of the patients who received erythropoietin treatment, 9 did not show hemoglobin improvement,
287 and 4 achieved a major response with transfusion independency.(21) Two patients received HMA with
288 azacitidine as a first line of treatment (n=1 died because of spontaneous bowel perforation and 1 was switched

289 to ruxolitinib due to inflammatory flare), whereas 1 patient received it as a second line. Remarkably, of the 2
290 patients with low-risk MDS progressing to AML, one (carrying the Met41Val genotype) evolved after one year,
291 while the other (Met41Thr) after two years since VEXAS onset.

292 Three patients underwent allogeneic allo-HCT from a MUD, preceded by reduced intensity conditioning (RIC)
293 based on treosulfan plus fludarabine (Treo/Flu). **Table S1** summarizes the clinical characteristics of these
294 patients. Transplant-related infective complications were registered in 2 cases: 1 patient had a sepsis sustained
295 by *Enterococcus faecium*, while the other experienced an invasive candidemia. Notably, no patient developed
296 Graft versus Host Disease (GvHD), and all 3 patients are alive and in clinical remission, 4 months, and 10 months
297 (n=2) following transplant.

298 With a median follow-up of 7.5 months (0.8-13.7), OS of the entire cohort was 95% at 1 year from VEXAS
299 symptoms onset (**Figure 2C**). At last follow-up, 5 patients (all with the Met41Thr genotype, the most common in
300 our cohort) died: 3 of infectious complications, 1 for spontaneous bowel perforation, and 1 for disease
301 progression to AML.

302 ***UBA1* clonal dynamics upon different therapeutics**

303 We quantified variations of the variant allele fraction (VAF) during the treatment of 4 patients, as shown in **Figure**
304 **3**. UPN1 had VEXAS with MDS/ myeloproliferative neoplasm (MDS/MPN) overlap syndrome and underwent
305 ruxolitinib treatment followed by allo-HCT. The PB sample analyzed at disease onset had a VAF of 46,6% which
306 increased to 58,1% after one month of treatment with ruxolitinib, and reached 85,7% at the pre-transplant control.
307 The post-transplant studies showed a near complete abatement of *UBA1* mutation already at +30 days after
308 transplantation in both BM and PB samples (VAF 0,01% and 0.007%, respectively).

309 The pre-transplant PB sample of UPN2 (VEXAS and Intermediate IPSS-R MDS) showed a 95% *UBA1*^{mut} VAF,
310 which dramatically decreased at + 30 days after allo-HCT (0,59%), at + 100 days (0,17%), until complete
311 disappearance at +180 and +365 days (VAF 0% in both determinations).

312 UPN3 had VEXAS and associated MDS and evolved to AML, as previously described.(15) Briefly, the patient
313 was treated with azacitidine-venetoclax but due to infectious complications temporarily stopped treatment and

eventually relapsed. We here describe his follow-up: upon improvement of the performance status, chemotherapy with 3+7 was started as a bridge to allo-HCT with rapid decrease of *UBA1* VAF from 23,9% before 3+7 chemotherapy, to 0,01% at +5 months from the transplant procedure.

UPN4 was a patient with VEXAS and associated low IPSS-R MDS for whom treatment with erythropoietin did not modify *UBA1* VAF (78,1% at +4 years of therapy, VAF 66,5% at + 8 years).

Discussion

In this study, we leveraged the Italian network of rheumatologists and hematologists to explore the diagnostic capabilities and clinical-genomic characteristics of VEXAS after 2.5 years since its first description.(1) Prompted by the novelty of the disorder and the lack of official guidelines, this nationwide survey has allowed us to gather information on techniques currently used to identify *UBA1* mutations, the clinical and genomic characteristics of patients with VEXAS diagnosed so far in Italy, and to investigate the different therapeutic approaches used. We also tracked longitudinal *UBA1* clonal dynamics upon a variety of treatments, confirming their disease-modifying capabilities, and potentially demonstrating its utility in the future for guiding therapeutic decisions and disease monitoring.

At least half of the responding centers had available *UBA1* diagnostics, with Sanger sequencing of exon 3 (location of the hotspot Met41(1, 22)) as the most common used method. As *UBA1* mutations are usually present at high VAFs²¹, Sanger sequencing may be a rapid and quite inexpensive first screening in highly suspicious patients.(5) However, new mutations have been defined in patients negative for canonical exon 3 variants and screened with other techniques(23) such as whole genome sequencing or WES(17), as also exemplified in our cohort. Therefore, while Sanger can be used in the first place, negative cases highly suspicious for VEXAS are the ideal candidates for *UBA1* whole gene sequencing methods.

In line with previous literature(24), our patients displayed a variety of clinical manifestations, with some being more constant and recurrent than others, namely BM vacuoles, male gender, and systemic inflammation. However, the heterogeneity of possible clinical scenarios poses challenges in disease recognition and clinical management, which is also hindered by the multidisciplinary nature of the condition.(8) In light of this, we showed

339 that a combination of competences across different specialties may guide clinical identification of suspected
340 cases, and their management in an individualized fashion, while waiting for official disease guidelines. It is then
341 unsurprising that in our cohort patients were treated with a variety of rheumatologic and hematologic therapies
342 with a median of 3 lines of treatments. Specific strategies have also been used in case of particular disease
343 manifestations. For instance, patients with thrombosis required anti-coagulation, while 3 cases with concomitant
344 MDS received allo-HCT. This is the only curative approach able to substitute the *UBA1*-mutant clonal
345 hematopoiesis and, as a result, abate the clinical manifestations of the disease, and anecdotal reports described
346 its utility in this setting.(13, 25, 26) Nonetheless, allo-HCT is burdened by a non-negligible mortality risk, and
347 should be judiciously pondered in patients such as those with VEXAS, typically old (median age in our cohort
348 was 67 years) and with a multitude of clinical conditions posing specific transplant challenges. Remarkably, we
349 showed that in all 3 cases allografted in our cohort, allo-HCT reverted the VEXAS clinical phenotypes and
350 parallelly cleared *UBA1* mutations. MDS/AML-directed approaches also decreased *UBA1* VAF, paralleling
351 clinical disease remissions as exemplified by UPN3. Conversely, we showed that ruxolitinib had only a
352 suspensive effect on VEXAS clinical manifestations while causing an increase of *UBA1* clonal burden in UPN1.
353 This is in line with Heiblig et al(27) who showed that, after treatment with ruxolitinib, the *UBA1* clone completely
354 overwhelmed the myeloid neoplastic clone in 2 VEXAS patients with respectively chromosome 7 deletion and
355 *JAK2* mutation.(27) Finally, supportive therapy with growth factors as erythropoietin did not alter *UBA1* kinetics,
356 as exemplified by UPN4.

357 Over the last decade, the link between BM aging and somatic mutations has been typified by the discovery of
358 clonal hematopoiesis of indeterminate potential (CHIP) in healthy, elderly individuals.(28-31) The aging
359 component is so relevant to this process that another acronym, ARCH (age-related clonal hematopoiesis) has
360 been coined to refer to the specific acquisition of mutations in myeloid genes, typically of the DAT (*DNMT3A*,
361 *ASXL1*, *TET2*) triad, in elderly individuals.(32) A growing line of research has then demonstrated the link between
362 occurrence of CHIP/ARCH and inflammation, with a known risk for carriers not only of myeloid neoplasia, but
363 also of cardiovascular events and increased all-cause mortality.(33) Obvious are the mechanistic analogies of
364 the above-mentioned conditions to VEXAS syndrome. Indeed, this is the first condition encompassing

365 CHIP/ARCH, “inflamm-aging” and MDS all together under the same nosological entity.(3) In our cohort, more
366 than two third of patients had concomitant MDS, and typically presented with lower IPSS-R/M risk profiles, as
367 substantiated by the low mutational burden with a landscape characteristics of ARCH. This finding is in line with
368 a recent report exploring the spectrum of clonal hematopoiesis associated with VEXAS by means of prospective
369 single-cell proteogenomic sequencing.(34) This study showed that *DNMT3A* mutations ontogenetically
370 preceded *UBA1* alterations, whereas *TET2* and other gene mutations occurred subclonally to *UBA1* or as
371 independent clones.(34, 35) It is noteworthy to mention that we previously reported the first case of VEXAS/MDS
372 evolving to AML, and here we describe a second case.(15) Both patients did not carry *DNMT3A* mutations,
373 perhaps arguing for clonal trajectories of these progressive cases more similar to that of general MDS than of
374 *UBA1/DNMT3A*-mutant VEXAS.(35) The latter may be instead the culmination of “inflamm-aging” forces driving
375 both ARCH and then *UBA1* mutational acquisition. (3)

376 In conclusions, we here present the Italian VEXAS experience taking advantage of a multidisciplinary network
377 of specialists, detailing the heterogeneous clinical and genomic characteristics of cases. Patients required a
378 variety of rheumatologic treatments and exhibited concomitant MDS in roughly 70% of cases. By tracking
379 longitudinal clonal dynamics, we were able to show *UBA1* clonal burden variations under different therapeutic
380 exposures including allo-HCT, the only treatment able to eradicate *UBA1* mutations, cure the disease and
381 currently explored in a phase II trial (NCT05027945). Follow-up to this study would be useful to identify the effects
382 of the various treatments on the clonal dynamics of the *UBA1* gene to spot potential prognostic factors and
383 accurately investigate minimal residual disease (MRD)-directed therapeutic strategies.(13)

385 **Acknowledgements**

386 We thank the patients and their families, the Italian Society of Experimental Hematology (SIES) and of
387 Rheumatology (SIR).

388 **References**

- 389 1. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic Mutations in UBA1 and
390 Severe Adult-Onset Autoinflammatory Disease. *N Engl J Med.* 2020;383(27):2628-38.
- 391 2. Grayson PC, Patel BA, Young NS. VEXAS syndrome. *Blood.* 2021;137(26):3591-4.
- 392 3. Gurnari C, Visconte V. From bone marrow failure syndromes to VEXAS: Disentangling clonal
393 hematopoiesis, immune system, and molecular drivers. *Leuk Res.* 2023;127:107038.
- 394 4. Poulter JA, Collins JC, Cargo C, De Tute RM, Evans P, Ospina Cardona D, et al. Novel somatic mutations
395 in UBA1 as a cause of VEXAS syndrome. *Blood.* 2021;137(26):3676-81.
- 396 5. Gurnari C, Pagliuca S, Durkin L, Terkawi L, Awada H, Kongkiatkamon S, et al. Vacuolization of
397 hematopoietic precursors: an enigma with multiple etiologies. *Blood.* 2021;137(26):3685-9.
- 398 6. Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H, Gutierrez-Rodrigues F, et al. Translation of
399 cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. *Blood.* 2022;140(13):1496-506.
- 400 7. Oganessian A, Hakobyan Y, Terrier B, Georgin-Lavialle S, Mekinian A. Looking beyond VEXAS:
401 Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome. *Semin*
402 *Hematol.* 2021;58(4):247-53.
- 403 8. Bruno A, Gurnari C, Alexander T, Snowden JA, Greco R. Autoimmune manifestations in VEXAS:
404 Opportunities for integration and pitfalls to interpretation. *J Allergy Clin Immunol.* 2023;151(5):1204-14.
- 405 9. Gurnari C, Mannion P, Pandit I, Pagliuca S, Voso MT, Maciejewski JP, et al. UBA1 Screening in Sweet
406 Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic
407 Myelomonocytic Leukemia. *Hemasphere.* 2022;6(10):e775.
- 408 10. Vitale A, Caggiano V, Bimonte A, Caroni F, Tosi GM, Fabbiani A, et al. VEXAS syndrome: a new
409 paradigm for adult-onset monogenic autoinflammatory diseases. *Intern Emerg Med.* 2023;18(3):711-22.
- 410 11. Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, et al. Estimated Prevalence and Clinical
411 Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. *Jama.*
412 2023;329(4):318-24.
- 413 12. Ma X. Epidemiology of myelodysplastic syndromes. *Am J Med.* 2012;125(7 Suppl):S2-5.

- 414 13. Gurnari C, McLornan DP. Update on VEXAS and role of allogeneic bone marrow transplant:
415 Considerations on behalf of the Chronic Malignancies Working Party of the EBMT. *Bone Marrow Transplant.*
416 2022;57(11):1642-8.
- 417 14. Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC, et al. Therapeutic options in
418 VEXAS syndrome: insights from a retrospective series. *Blood.* 2021;137(26):3682-4.
- 419 15. Battipaglia G, Vincenzi A, Falconi G, Fiore A, D'Agostino F, Iannotta R, et al. New scenarios in Vacuoles,
420 E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome
421 to acute myeloid leukemia. *Curr Res Transl Med.* 2023;71(2):103386.
- 422 16. Falconi G, Fabiani E, Piciocchi A, Criscuolo M, Fianchi L, Lindfors Rossi EL, et al. Somatic mutations as
423 markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic
424 syndromes. *Leukemia.* 2019;33(3):785-90.
- 425 17. Stiburkova B, Pavelcova K, Belickova M, Magaziner SJ, Collins JC, Werner A, et al. Novel Somatic UBA1
426 Variant in a Patient With VEXAS Syndrome. *Arthritis Rheumatol.* 2023;75(7):1285-90.
- 427 18. Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, et al. Time-dependent changes
428 in mortality and transformation risk in MDS. *Blood.* 2016;128(7):902-10.
- 429 19. Bernard E, Tuechler H, Greenberg Peter L, Hasserjian Robert P, Arango Ossa Juan E, Nannya Y, et al.
430 Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. *NEJM Evidence.*
431 2022;1(7):EVIDoA2200008.
- 432 20. Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U. Myelodysplastic syndromes: ESMO
433 Clinical Practice Guidelines for diagnosis, treatment and follow-up(†☆). *Ann Oncol.* 2021;32(2):142-56.
- 434 21. Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, et al. Proposals for
435 revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. *Blood.*
436 2019;133(10):1020-30.
- 437 22. Heiblig M, Patel B, Jamilloux Y. VEXAS syndrome, a new kid on the block of auto-inflammatory diseases:
438 A hematologist's point of view. *Best Pract Res Clin Rheumatol.* 2023:101861.

- 439 23. Sakuma M, Blombery P, Meggendorfer M, Haferlach C, Lindauer M, Martens UM, et al. Novel causative
440 variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of
441 hematological malignancies. *Leukemia*. 2023;37(5):1080-91.
- 442 24. Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al. Further characterization
443 of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116
444 French patients. *Br J Dermatol*. 2022;186(3):564-74.
- 445 25. Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L, et al. Successful allogeneic
446 hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. *Blood Adv*.
447 2022;6(3):998-1003.
- 448 26. Mangaonkar AA, Langer KJ, Lasho TL, Finke C, Litzow MR, Hogan WJ, et al. Reduced intensity
449 conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective
450 series of patients. *Am J Hematol*. 2023;98(2):E28-e31.
- 451 27. Heiblig M, Ferrada MA, Koster MJ, Barba T, Gerfaud-Valentin M, Mékinian A, et al. Ruxolitinib is more
452 effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. *Blood*.
453 2022;140(8):927-31.
- 454 28. Bejar R. CHIP, ICUS, CCUS and other four-letter words. *Leukemia*. 2017;31(9):1869-71.
- 455 29. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. *Science*. 2019;366(6465).
- 456 30. Jaiswal S. Clonal hematopoiesis and nonhematologic disorders. *Blood*. 2020;136(14):1606-14.
- 457 31. Mitchell E, Spencer Chapman M, Williams N, Dawson KJ, Mende N, Calderbank EF, et al. Clonal
458 dynamics of haematopoiesis across the human lifespan. *Nature*. 2022;606(7913):343-50.
- 459 32. Shlush LI. Age-related clonal hematopoiesis. *Blood*. 2018;131(5):496-504.
- 460 33. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal
461 hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371(26):2488-98.
- 462 34. Gutierrez-Rodrigues F, Kusne Y, Fernandez J, Lasho T, Shalhoub R, Ma X, et al. Spectrum of clonal
463 hematopoiesis in VEXAS syndrome. *Blood*. 2023;142(3):244-59.
- 464 35. Malcovati L. VEXAS: walking on the edge of malignancy. *Blood*. 2023;142(3):214-5.

465 **Tables**466 **Table 1. Clinical characteristics of patients with VEXAS syndrome (n=41).**

Characteristics	
Male gender, n (%)	41 (100)
Age in years at diagnosis, median (IQR)	67 (62-72)
Chondritis, n (%)	20 (49)
Skin lesions, n (%)	14 (34)
BM vacuoles*, n (%)	32 (89)
Laboratory data	
Hemoglobin (g/dl), median (IQR)	9.1 (8-11)
Platelets (x 10 ⁹ /L), median (IQR)	127,000 (87,000-172,000)
Leucocytes (x 10 ⁹ /L), median (IQR)	3,800 (2,540-5,900)
Neutrophils (x 10 ⁹ /L), median (IQR)	2,020 (1,200-3,700)
Unprovoked thrombosis*, n (%)	11 (28)
VEXAS therapy*	1
No treatment, n (%)	3
Steroids**, n (%)	33 (83)
DMARDs**, n (%)	20 (50)
Azacitidine**, n (%)	3 (8)
Concomitant hematological disorders*	
MM, n (%)	0
MGUS, n (%)	15 (37)
MDS, n (%)	28 (71)
Progression MDS to AML, n (%)	2 (7)
Deaths, n (%)	5 (12)

467 *Missing data, percentage calculated on cases with available information; **ever received.

468

469

470

471

472

473

474 **Figure legends**

475 **Figure 1. Italian cartography of VEXAS and clinical manifestation.** A) Map of Italy highlighting the centers
476 that had available *UBA1* genomic testing. B) A bar chart showcases the diagnostic techniques used in the Italian
477 centers. C) May Grünwald-Giemsa staining of bone marrow aspirate from a representative patient with VEXAS
478 depicting the phenomenon of vacuolization of the hematopoietic precursors. D): Clinical manifestations of
479 VEXAS in our cohort.

480 **Figure 2. VEXAS associations and outcomes.** Panel A) shows a pie chart with patients with VEXAS syndrome
481 and presence of MDS classified in accordance with guidelines from the World Health Organization (WHO) 2022.
482 Panel B) shows IPSS-R e IPSS-M distribution of cases with MDS-associated VEXAS syndrome (percentages
483 are calculated on cases with available information). Panel C) Kaplan Meier curve and 95% confidence interval
484 for the entire cohort. Numbers at risk are indicated below the curve.

485 **Figure 3. *UBA1* clonal dynamics upon different therapeutics.** Graphs showing the clonal dynamics of the
486 *UBA1* gene, studied by means of ddPCR, in 4 patients who underwent different treatment approaches.

487